DK2925329T3 - Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet - Google Patents

Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet Download PDF

Info

Publication number
DK2925329T3
DK2925329T3 DK13859049.2T DK13859049T DK2925329T3 DK 2925329 T3 DK2925329 T3 DK 2925329T3 DK 13859049 T DK13859049 T DK 13859049T DK 2925329 T3 DK2925329 T3 DK 2925329T3
Authority
DK
Denmark
Prior art keywords
transplants
cyclophosphamide
bone marrow
infiltrating lymphocytes
antitumor immunity
Prior art date
Application number
DK13859049.2T
Other languages
English (en)
Inventor
Ivan Marques Borrello
Kimberly Ann Noonan
Leonido Luznik
Original Assignee
Ivan Marques Borrello
Kimberly Ann Noonan
Leonido Luznik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivan Marques Borrello, Kimberly Ann Noonan, Leonido Luznik filed Critical Ivan Marques Borrello
Application granted granted Critical
Publication of DK2925329T3 publication Critical patent/DK2925329T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK13859049.2T 2012-11-27 2013-11-26 Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet DK2925329T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730239P 2012-11-27 2012-11-27
PCT/US2013/071975 WO2014085437A2 (en) 2012-11-27 2013-11-26 Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity

Publications (1)

Publication Number Publication Date
DK2925329T3 true DK2925329T3 (da) 2021-03-22

Family

ID=50828589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13859049.2T DK2925329T3 (da) 2012-11-27 2013-11-26 Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet

Country Status (5)

Country Link
EP (1) EP2925329B1 (da)
DK (1) DK2925329T3 (da)
ES (1) ES2862433T3 (da)
PT (1) PT2925329T (da)
WO (1) WO2014085437A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
ES2909662T3 (es) * 2014-08-07 2022-05-09 Laevoroc Immunology Ag Composiciones que comprenden un inhibidor de PNP para uso en el tratamiento de la recaída de malignidad después de un trasplante de células madre hematopoyéticas
AU2015311761B2 (en) 2014-09-04 2020-11-12 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
MA42902A (fr) * 2015-07-08 2018-05-16 Univ Johns Hopkins Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364152A4 (en) * 2008-11-03 2013-02-13 Univ Johns Hopkins METHOD FOR PRODUCING AND USING MARKINFILTRATING LYMPHOCYTES (MILS)

Also Published As

Publication number Publication date
ES2862433T3 (es) 2021-10-07
WO2014085437A2 (en) 2014-06-05
PT2925329T (pt) 2021-03-29
EP2925329A4 (en) 2016-08-17
EP2925329B1 (en) 2021-01-06
EP2925329A2 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
DK2925329T3 (da) Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet
EP2906699A4 (en) OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
DK3725778T3 (da) Formuleringer af enzalutamid
GB201316386D0 (en) Generating routes to optimise traffic flow
DK2911506T3 (da) Driftreducerende sammensætninger
GB201302025D0 (en) Improvements in or relating to prosthetics
SG11201504466UA (en) Cooling-equipment working-fluid composition
ZA201501809B (en) Hydrogen-regenerating solar-powered aircraft
EP2862114A4 (en) APPLICATION SERVICE REGISTRATION FOR APPLICATION APPLICATION
EP2958523A4 (en) CARTEL MUSAIC COMPOSITIONS AND METHODS
SG11201500927YA (en) Kimono
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK2938486T3 (da) Kompositglas
ITMI20131372A1 (it) Cerchione composito di bicicletta
DK2852392T3 (da) Anvendelser af ikke-sulfateret chondroitin
DK2838850T3 (da) Oprensning af titantetrachlorid
SG11201404141QA (en) Desrhamnosyl acteoside-containing olive extract
GB201214745D0 (en) Separation of components within fluids
FR2987600B1 (fr) Nacelle aplatie de turboreacteur
HK1202386A1 (en) Multi-functional necktie
AP2015008378A0 (en) Improvements relating to buoyancy-supported risers
GB201215007D0 (en) Improvements in or relating to luminaires
DK2809085T3 (da) Indretning til at estimere placering af fysiske objekter
FR2994041B1 (fr) Systeme de multi-transmission unidirectionnelle
CO7071132A2 (es) Composiciones de acción prolongada